ThermoGenesis to Present at the Rodman & Renshaw(R) Annual Global Investment Conference
RANCHO CORDOVA, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today announced that Matthew Plavan, Chief Executive Officer of ThermoGenesis, and Kenneth Harris, Chairman and Chief Executive Officer of TotipotentRx Corporation, will present at the Rodman & Renshaw® Annual Global Investment Conference, being held at the Millennium Broadway Hotel in New York City. The presentation will take place on Monday, September 9, 2013 at 12:05 PM Eastern Time.
The presentation will be webcast and available to the public online at wsw.com/webcast/rrshq23/kool. A replay will be available for 30 days after the presentation.
About ThermoGenesis Corp.
ThermoGenesis Corp. ( www.thermogenesis.com ) is a leader in developing and manufacturing automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. These include:
- The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells from bone marrow aspirates in the laboratory setting.
- The Res-QTM 60 (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
TotipotentRx and ThermoGenesis Corp recently announced their entry into a merger agreement which will operate under the name Cesca Therapeutics. The merger is subject to TotipotentRx and ThermoGenesis stockholder approval.
In connection with the merger, ThermoGenesis intends to file a registration statement (including a prospectus) on Form S-4 with the Securities and Exchange Commission. Holders of TotipotentRX Corporation Common Stock are urged to read the proxy statement/prospectus and any other relevant documents when filed because they contain important information about ThermoGenesis and the merger. A proxy statement will be sent to holders of our Common Stock and a proxy statement/prospectus will be sent to holders of TotipotentRX Corporation common stock. When filed, the proxy statement/prospectus and other documents relating to the proposed merger can be obtained free of charge from the SEC's website at www.sec.gov . These documents can also be obtained free of charge from ThermoGenesis upon written request to ThermoGenesis Corporation, Investor Relations, 2711 Citrus Road Rancho Cordova, CA 95742.
CONTACT: ThermoGenesis Corp. Investor Relations +1-916-858-5107, or firstname.lastname@example.org http://www.thermogenesis.com
Source: ThermoGenesis Corp. 2013 GlobeNewswire, Inc.